News & Views
Lab21 acquires Microgen Bioproducts
Mar 17 2011
Lab21 Ltd, a specialist in personalised medicine and clinical diagnostics, has acquired Microgen Bioproducts Ltd a UK company specialising in the development, manufacture and sale of diagnostic tests to identify diseases and organisms which pose a threat to health. The company’s expertise in microbiological assay development and commercialisation complements Lab21’s extensive diagnostics portfolio particularly in the infectious disease market. This transaction provides further expansion of Lab21’s distribution channel in key territories including the US, UK, Europe and Asia.
Graham Mullis, CEO of Lab21, said: “Microgen Bioproducts is a well established and profitable business which will significantly contribute to our growth plans in our core products division. This acquisition highlights Lab21’s commitment to continuing its exciting roll-up strategy and we expect to bring other high quality acquisitions into the Group during 2011.”
Dan Deery, Managing Director of Microgen Bioproducts, added: “Lab21 has built a strong reputation, with a global reach and innovative products. We are delighted to join forceswith them.”
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE